Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating on Kura Oncology (NASDAQ: KURA).The analyst commented, "Beyond the menin launch ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments